InMed Pharmaceuticals is a Vancouver-based biopharmaceutical company focusing on developing therapies using rare cannabinoids, particularly for treating neurodegenerative, dermatological, and ocular diseases. InMed’s research and product pipeline are primarily centered on leveraging synthetic cannabinoids, like cannabinol (CBN), to address unmet medical needs across several disease areas. One of their promising products, INM-755, is a topical… Continue reading InMed Pharmaceuticals – Hope and Consolidation
Vice President Kamala Harris has recently advocated for changes in U.S. marijuana policy, emphasizing the need to reschedule the drug and ultimately legalize it at the federal level. Harris criticized the current classification of marijuana as a Schedule I substance—on par with heroin—calling it “absurd” and advocating for swift action to reclassify it. This change… Continue reading Kamala Harris Shows Support for Marijuana Reform: Get Ready to Get your Share
Pot Stocks continue to rip the day after news came out that The House of Representatives may consider the MORE act. bill next week. Tilray (TLRY), Sundial (SNDL), Canopy Growth (CGC), Aurora (ACB) and Cronos (CRON) are up 5% to 20% as of this morning. Though it may be short lived as it is expected… Continue reading Pot Stocks continue to rip
Sundial (SNDL), Aurora Cannabis (ACB), Tilray (TLRY), Cronos Group (CRON) and Cleaver Leaves (CLVR) are on the rise in after hours. Following a report that the house rules Committee has scheduled a Monday-afternoon meeting to prepare a federal marijuana legalization bill for floor action, all the big names in the cannabis industry surged on the… Continue reading Cannabis Stocks are Getting High(er)